TY - JOUR
T1 - Pathogenesis of NASH
T2 - the Impact of Multiple Pathways
AU - Noureddin, Mazen
AU - Sanyal, Arun J.
N1 - Publisher Copyright:
© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2018.
PY - 2018/12
Y1 - 2018/12
N2 - Purpose of review: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. Recent findings: Recent findings on NASH pathogenesis have expanded our understanding of its complexity including (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy. Summary: Recent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors, and FXR agonists. Further, advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies.
AB - Purpose of review: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. Recent findings: Recent findings on NASH pathogenesis have expanded our understanding of its complexity including (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy. Summary: Recent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors, and FXR agonists. Further, advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies.
KW - Cirrhosis
KW - Fibrosis
KW - Microbiome
KW - Nonalcoholic fatty liver disease (NAFLD)
KW - Nonalcoholic steatohepatitis (NASH)
KW - ROS (reactive oxygen species)
UR - https://www.scopus.com/pages/publications/85073373823
UR - https://www.scopus.com/inward/citedby.url?scp=85073373823&partnerID=8YFLogxK
U2 - 10.1007/s11901-018-0425-7
DO - 10.1007/s11901-018-0425-7
M3 - Article
AN - SCOPUS:85073373823
SN - 2195-9595
VL - 17
SP - 350
EP - 360
JO - Current Hepatology Reports
JF - Current Hepatology Reports
IS - 4
ER -